drugset
drugset / Trial / NCT04353830

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

NCT04353830 ↗

Phase 1 Completed 34 enrolled Innovent Biologics (Suzhou) Co. Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies

Timeline

Start
2020-05-22
Primary completion
2022-05-11
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI939 Protein / enzyme biologic — Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

cancer